Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Innovent Starts China Trials of PD-1/PD-L1 Bispecific Antibody

publication date: Apr 24, 2019

Innovent Biologics (Suzhou) has dosed the first patient in a Phase I trial of a bispecific antibody that targets both PD-1 and PD-L1. According to Innovent, the candidate (IBI318) is the first PD-1/PDL1 bispecific to start clinical trials anywhere in the world. Innovent discovered and partnered IBI318 with Lilly as part of their $1 billion agreement, announced in 2015. The China Phase I trial will test the candidate for safety, tolerability and initial efficacy in patients with advanced malignancies. More details....

Stock Symbols: (HK: 01801) (NYSE: LLY)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China